Skip to main content
Psychedex
Sources
24
1 strong · 17 moderate · 6 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
74
46verified2partial26inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 8, 2026 · pipeline-v5
Values approved
96/98 (98%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold0.1 mg0.1 mglow
Low0.1–0.2 mg0.1–0.2 mglow
Common0.2–0.3 mg0.2–0.3 mglow
Strong0.3–0.5 mg0.3–0.5 mglow
Heavy0.5+ mg0.5+ mglow
Editorial

Existing DB seed values carried forward: threshold 0.1 mg, light 0.1-0.2, common 0.2-0.3, strong 0.3-0.5, heavy 0.5+. Partially supported by Ameline 2019 self-administration study at 0.25 mg (sits within common range as a 'labeled dosage'). No independent dose-finding study exists. Ranges are community-derived with weak substance-specific published support. Sub-milligram dosing makes volumetric dilution essential.

Reasoning

Existing DB seed values carried forward: threshold 0.1 mg, light 0.1-0.2, common 0.2-0.3, strong 0.3-0.5, heavy 0.5+. Partially supported by Ameline 2019 self-administration study at 0.25 mg (sits within common range as a 'labeled dosage'). No independent dose-finding study exists. Ranges are community-derived with weak substance-specific published support. Sub-milligram dosing makes volumetric dilution essential.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Offsettrace2–4 hours2–4 hourslow
Editorial

Existing DB seed value (2-4 hours). Consistent with estimated half-life of 5-13 hours (unverified secondary sources) and class pharmacology.

Reasoning

Existing DB seed value (2-4 hours). Consistent with estimated half-life of 5-13 hours (unverified secondary sources) and class pharmacology.

Evidence basis: community_consensus_large

Onsettrace20–40 minutes20–40 minutesmedium
Editorial

Existing DB seed value (20-40 minutes), consistent with Ameline 2019 metabolite detection kinetics and oral absorption expectations for a lipophilic triazolobenzodiazepine.

Reasoning

Existing DB seed value (20-40 minutes), consistent with Ameline 2019 metabolite detection kinetics and oral absorption expectations for a lipophilic triazolobenzodiazepine.

Evidence basis: community_consensus_large

Come uptrace10–20 minutes10–20 minuteslow
Editorial

No seed data for come_up phase. Estimated from onset-to-peak timing: onset ends ~20-40 min, peak begins ~40-60 min, leaving a 10-20 min come_up window. Work-notes flag this as confidence=low.

Reasoning

No seed data for come_up phase. Estimated from onset-to-peak timing: onset ends ~20-40 min, peak begins ~40-60 min, leaving a 10-20 min come_up window. Work-notes flag this as confidence=low.

Evidence basis: structural_analogy

Peaktrace1–2 hours1–2 hourslow
Editorial

Existing DB seed value (1-2 hours). Consistent with Ameline 2019 metabolite detection kinetics and class pharmacology of short-to-intermediate acting triazolobenzodiazepines (reference: triazolam peak ~1-2 hr).

Reasoning

Existing DB seed value (1-2 hours). Consistent with Ameline 2019 metabolite detection kinetics and class pharmacology of short-to-intermediate acting triazolobenzodiazepines (reference: triazolam peak ~1-2 hr).

Evidence basis: community_consensus_large

Totaltrace4–8 hours4–8 hourslow
Editorial

Existing DB seed value (4-8 hours). Represents subjective experience duration only, not pharmacological half-life or metabolite detection window (which extends to 37 hours per Ameline 2019).

Reasoning

Existing DB seed value (4-8 hours). Represents subjective experience duration only, not pharmacological half-life or metabolite detection window (which extends to 37 hours per Ameline 2019).

Evidence basis: community_consensus_large

After effectstrace1–12 hours1–12 hourslow
Editorial

Existing DB seed value (1-12 hours). Wide range reflects inter-individual variability and dose-dependent residual effects including cognitive fog, drowsiness, and possible next-day impairment. The upper bound accounts for the estimated 5-13h elimination half-life.

Reasoning

Existing DB seed value (1-12 hours). Wide range reflects inter-individual variability and dose-dependent residual effects including cognitive fog, drowsiness, and possible next-day impairment. The upper bound accounts for the estimated 5-13h elimination half-life.

Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutehighhighmedium
Chronicmoderatemoderatemedium
Organs Affectedpulmonary, hepatic, neurologicalpulmonary, hepatic, neurologicalmedium
Editorial

Acute=high supported by substance-specific in vitro potency data (LOEC 0.01 µM, Wopken 2026), documented clinical intoxication cases (STRIDA project, Helander 2017/Bäckberg 2019), and sub-milligram dosing precision risk. Chronic downgraded from work-notes 'high' to 'moderate' per evidence discount rule — no substance-specific chronic toxicity data; organ damage inferred entirely from benzodiazepine class pharmacology (reference: diazepam, alprazolam chronic exposure literature). Seed data contained internal contradiction ('low toxicity' note vs 'Acute: high') — resolved toward high based on potency and intoxication evidence.

Reasoning

Acute=high supported by substance-specific in vitro potency data (LOEC 0.01 µM, Wopken 2026), documented clinical intoxication cases (STRIDA project, Helander 2017/Bäckberg 2019), and sub-milligram dosing precision risk. Chronic downgraded from work-notes 'high' to 'moderate' per evidence discount rule — no substance-specific chronic toxicity data; organ damage inferred entirely from benzodiazepine class pharmacology (reference: diazepam, alprazolam chronic exposure literature). Seed data contained internal contradiction ('low toxicity' note vs 'Acute: high') — resolved toward high based on potency and intoxication evidence.

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighmedium
Psychologicalhighhighmedium
Compulsive Redosinghighhighmedium
Dose Escalationhighhighmedium
Editorial

No flunitrazolam-specific dependence studies exist. All parameters extrapolated from well-characterized class pharmacology of high-potency short-acting benzodiazepines (reference compounds: triazolam, alprazolam; designer class siblings: clonazolam). Navarrete et al. 2026 reviewed benzodiazepine dependence mechanisms. Medium confidence reflects class extrapolation without substance-specific confirmation.

Reasoning

No flunitrazolam-specific dependence studies exist. All parameters extrapolated from well-characterized class pharmacology of high-potency short-acting benzodiazepines (reference compounds: triazolam, alprazolam; designer class siblings: clonazolam). Navarrete et al. 2026 reviewed benzodiazepine dependence mechanisms. Medium confidence reflects class extrapolation without substance-specific confirmation.

Evidence basis: structural_analogy

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitylife_threateninglife_threateningmedium
Symptomsrebound anxiety, insomnia, tremor, diaphoresis, perceptual disturbances, seizures, deliriumrebound anxiety, insomnia, tremor, diaphoresis, perceptual disturbances, seizures, deliriummedium
FatalYesYesmedium
Medical SupervisionRequiredRequiredmedium
Editorial

Withdrawal profile inferred from benzodiazepine class pharmacology (Navarrete et al. 2026, Weaver 2015). Short-to-intermediate half-life (est. 5-13h) predicts earlier withdrawal onset than long-acting benzodiazepines. Seizures and delirium are documented life-threatening complications of benzodiazepine withdrawal. No flunitrazolam-specific withdrawal data exist.

Reasoning

Withdrawal profile inferred from benzodiazepine class pharmacology (Navarrete et al. 2026, Weaver 2015). Short-to-intermediate half-life (est. 5-13h) predicts earlier withdrawal onset than long-acting benzodiazepines. Seizures and delirium are documented life-threatening complications of benzodiazepine withdrawal. No flunitrazolam-specific withdrawal data exist.

Evidence basis: structural_analogy

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidmedium
Half-life3.5 days3.5 daysmedium
Full Reset10.5 days10.5 daysmedium
Cross-tolerancesbenzodiazepines, zolpidem, zopiclone, alcohol, barbituratesbenzodiazepines, zolpidem, zopiclone, alcohol, barbituratesmedium
Editorial

Tolerance parameters from seed data (buildup: days, reset: 10.5 days) consistent with benzodiazepine class pharmacology reviewed by Navarrete et al. 2026. Half-life of 3.5 days for tolerance is derived from the 10.5-day full reset (approximately 3 half-lives). Cross-tolerances are class-level. All values are structural analogy from triazolam/alprazolam.

Reasoning

Tolerance parameters from seed data (buildup: days, reset: 10.5 days) consistent with benzodiazepine class pharmacology reviewed by Navarrete et al. 2026. Half-life of 3.5 days for tolerance is derived from the 10.5-day full reset (approximately 3 half-lives). Cross-tolerances are class-level. All values are structural analogy from triazolam/alprazolam.

Evidence basis: structural_analogy

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
respiratory Concurrent CNS depressant usetraceabsoluteabsolutehigh
Editorial

Documented co-intoxication cases from STRIDA project (Helander et al. 2017) plus well-established class pharmacology of additive CNS/respiratory depression. Substance-specific forensic evidence supports this contraindication.

Reasoning

Documented co-intoxication cases from STRIDA project (Helander et al. 2017) plus well-established class pharmacology of additive CNS/respiratory depression. Substance-specific forensic evidence supports this contraindication.

respiratory Respiratory insufficiencytraceabsoluteabsolutehigh
Editorial

Class-level benzodiazepine contraindication supported by established respiratory depression mechanism. No flunitrazolam-specific data, but respiratory depression is documented in clinical intoxication cases.

Reasoning

Class-level benzodiazepine contraindication supported by established respiratory depression mechanism. No flunitrazolam-specific data, but respiratory depression is documented in clinical intoxication cases.

hepatic Hepatic impairmenttracerelativerelativemedium
Editorial

Substance-specific metabolic data (anomalous UGT profile from Pettersson Bergstrand 2019) combined with class-level hepatic metabolism dependence. The unusual UGT requirement elevates this beyond standard class-level hepatic contraindication.

Reasoning

Substance-specific metabolic data (anomalous UGT profile from Pettersson Bergstrand 2019) combined with class-level hepatic metabolism dependence. The unusual UGT requirement elevates this beyond standard class-level hepatic contraindication.

pregnancy breastfeeding Pregnancytracerelativerelativemedium
Editorial

Class extrapolation from established benzodiazepine teratogenicity data (reference compounds: diazepam, alprazolam). No flunitrazolam-specific reproductive studies exist.

Reasoning

Class extrapolation from established benzodiazepine teratogenicity data (reference compounds: diazepam, alprazolam). No flunitrazolam-specific reproductive studies exist.

psychiatric History of substance use disordertracerelativerelativemedium
Editorial

Class-level contraindication supported by established reinforcement pharmacology of high-potency short-acting benzodiazepines (reference: triazolam, alprazolam). Compulsive redosing is consistently reported for flunitrazolam.

Reasoning

Class-level contraindication supported by established reinforcement pharmacology of high-potency short-acting benzodiazepines (reference: triazolam, alprazolam). Compulsive redosing is consistently reported for flunitrazolam.

neurological Myasthenia gravistracerelativerelativelow
Editorial

Class-level inference from benzodiazepine muscle relaxant properties. No substance-specific or even class-specific controlled data for this specific interaction. Low confidence reflects pure structural analogy.

Reasoning

Class-level inference from benzodiazepine muscle relaxant properties. No substance-specific or even class-specific controlled data for this specific interaction. Low confidence reflects pure structural analogy.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Resolutiontrace5400–7200 sec(i=0.50)5400–7200 sec(i=0.50)low
Editorial

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Reasoning

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Evidence basis: community_consensus_large

Onsettrace900–1200 sec(i=0.05)900–1200 sec(i=0.05)low
Editorial

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Reasoning

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Evidence basis: community_consensus_large

Come uptrace600–1200 sec(i=0.30)600–1200 sec(i=0.30)low
Editorial

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Reasoning

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Evidence basis: community_consensus_large

Peaktrace2700–4500 sec(i=1.00)2700–4500 sec(i=1.00)low
Editorial

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Reasoning

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Evidence basis: community_consensus_large

Afterglowtrace14400–28800 sec(i=0.15)14400–28800 sec(i=0.15)low
Editorial

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Reasoning

Timeline derived from seed duration data (onset 20-40 min, peak 1-2 hr, offset 2-4 hr, aftereffects 1-12 hr, total 4-8 hr) consistent with Ameline 2019 metabolite detection kinetics. Come_up phase interpolated from onset-to-peak timing. No controlled subjective duration study exists; all values are community-derived with pharmacokinetic support from urinary metabolite windows.

Evidence basis: community_consensus_large

Dose Tier Summaries

thresholdtrace
low

Minimal perceptible effect at the edge of detection. A subtle anxiolysis and mild calming sensation emerge without significant sedation or cognitive impairment. Most users describe a faint sense of relaxation that could be mistaken for placebo. No anterograde amnesia is expected at this level. Physical effects are negligible — slight muscle relaxation may be noticeable if specifically attended to, but motor coordination and respiratory function remain unaffected. No dizziness or physical fatigue. Functional capacity is fully preserved. This dose level is primarily relevant as a reference point for volumetric dilution calibration. Sub-milligram measurement requires dissolved solution dosing for any precision.

Editorial

Work-notes threshold outline expanded. No controlled dose-finding data exist; threshold inferred from community reports and the lower bound of the seed dose range (0.1 mg). Confidence low due to absence of substance-specific dose-response studies.

Reasoning

Work-notes threshold outline expanded. No controlled dose-finding data exist; threshold inferred from community reports and the lower bound of the seed dose range (0.1 mg). Confidence low due to absence of substance-specific dose-response studies.

Evidence basis: community_consensus_large

lighttrace
low

Noticeable anxiolysis becomes the dominant subjective experience, accompanied by mild sedation and the beginning of muscle relaxation. Thought deceleration is perceptible — mental processing feels slightly slower and less urgent. Social function remains largely preserved, though subtle disinhibition may be apparent to close observers. Physically, mild bodily heaviness and warmth may emerge. Motor coordination is minimally impaired. No significant respiratory effects at this level. Mild dizziness is possible at the upper end of the range. Memory encoding may begin to weaken at the upper boundary — occasional gaps rather than frank amnesia. Compulsive redosing urge is low but present. Volumetric dosing remains essential for measurement accuracy.

Editorial

Work-notes light tier outline expanded. Values inferred from community consensus and structural analogy to triazolam/alprazolam at equipotent light doses. No substance-specific dose-response data.

Reasoning

Work-notes light tier outline expanded. Values inferred from community consensus and structural analogy to triazolam/alprazolam at equipotent light doses. No substance-specific dose-response data.

Evidence basis: community_consensus_large

commontrace
medium

Clear sedation dominates the experience alongside marked anxiety suppression and muscle relaxation. Anterograde amnesia becomes apparent — memory of events during exposure is patchy and unreliable. Cognitive processing is noticeably slowed, with analysis suppression and information processing suppression clearly present. Emotional suppression flattens affective range. Physical effects include moderate motor control impairment, bodily heaviness, and mild dizziness. Physical fatigue may encourage lying down. Respiratory depression remains subclinical at this dose in healthy individuals but is dose-dependent. Disinhibition is present and delusions of sobriety may begin — users may believe they are less impaired than they are. Compulsive redosing risk increases as amnesia impairs recall of prior doses. This is the dose range where the defining risk pattern of flunitrazolam emerges: ambulatory blackout with continued redosing.

Editorial

Work-notes common tier expanded. Ameline 2019 studied 0.25 mg (sits within common range), confirming metabolic activity at this dose. Effects profile extrapolated from class pharmacology of triazolam/clonazolam at equivalent doses and community reports.

Reasoning

Work-notes common tier expanded. Ameline 2019 studied 0.25 mg (sits within common range), confirming metabolic activity at this dose. Effects profile extrapolated from class pharmacology of triazolam/clonazolam at equivalent doses and community reports.

Evidence basis: community_consensus_large

strongtrace
low

Heavy sedation approaching hypnosis. Anterograde amnesia is typically complete — extended blackout periods are the norm rather than the exception. Users may remain ambulatory and conversational while forming no memories whatsoever. Thought disorganization is pronounced and confusion is common. Cognitive euphoria may be present as a diffuse sense of relief, though cognitive impairment dominates the experience. Motor control impairment is marked, with visible ataxia and slurred speech. Physical fatigue is heavy. Respiratory depression becomes clinically relevant, particularly in combination with any other CNS depressant. Dizziness and double vision may occur. Delusions of sobriety are at their most dangerous here — the subjective sense of being 'fine' persists despite objective incapacitation. Compulsive redosing risk is high because amnestic users cannot recall having dosed. This dose level carries significant risk of harm from impaired decision-making during blackout states.

Editorial

Work-notes strong tier expanded. No controlled human data at this dose level. Effects extrapolated from clinical intoxication presentations (STRIDA case series) and structural analogy to triazolam/clonazolam strong-dose profiles.

Reasoning

Work-notes strong tier expanded. No controlled human data at this dose level. Effects extrapolated from clinical intoxication presentations (STRIDA case series) and structural analogy to triazolam/clonazolam strong-dose profiles.

Evidence basis: community_consensus_large

heavytrace
low

Loss of consciousness is likely. Complete anterograde amnesia extends to the entire exposure period and potentially beyond. Users who remain conscious display severe ataxia, incoherent speech, and profound cognitive impairment indistinguishable from severe alcohol intoxication. Respiratory depression becomes the primary acute safety concern — particularly dangerous when combined with opioids, alcohol, or other CNS depressants, where synergistic respiratory failure can be fatal. Aspiration during unconsciousness is an additional risk. Profound physical sedation and muscle relaxation. This dose level represents a medical emergency risk. The sub-milligram active range means heavy doses can result from small weighing errors or inconsistent product potency. Emergency reversal with flumazenil may be required, with naloxone co-administered if opioid co-ingestion is suspected.

Editorial

Work-notes heavy tier expanded. Effects inferred from STRIDA clinical intoxication case series (polydrug context), class pharmacology of benzodiazepine overdose, and the known respiratory depression mechanism. No controlled data at this dose level.

Reasoning

Work-notes heavy tier expanded. Effects inferred from STRIDA clinical intoxication case series (polydrug context), class pharmacology of benzodiazepine overdose, and the known respiratory depression mechanism. No controlled data at this dose level.

Evidence basis: structural_analogy

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

1 strong · 17 moderate · 6 weak
  1. [1]
    moderate
    Inhibitory effects of (synthetic) cannabinoids and (designer) benzodiazepines on spontaneously active neuronal networks of primary rat cortical cultures in vitro
    Wopken JP, Thornton JR, van Kleef RGDM, Westerink RHS · 2026 · Neurotoxicology
    doi.org/10.1016/j.neuro.2025.103379pubmed 414821667 claims checked6 verified1 partial
  2. [2]
    moderate
    The emergence of new psychoactive substance (NPS) benzodiazepines: A review.
    Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD · 2018 · Drug testing and analysis
    doi.org/10.1002/dta.2211pubmed 2847109612 claims checked2 verified10 inconclusive
  3. [3]
    moderate
    Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches.
    Navarrete F, Marín-Mayor M, Martínez-Hostyn L, Rubio G, Manzanares J · 2026 · International journal of molecular sciences
    doi.org/10.3390/ijms27031430pubmed 416838528 claims checked6 verified2 inconclusive
  4. [4]
    weak
    Flunitrazolam - HandWiki Chemistry entry
    HandWiki · 2023
    linkno claims checked
  5. [5]
    moderate
    Intoxications involving acrylfentanyl and other novel designer fentanyls – results from the Swedish STRIDA project
    Helander A, Bäckberg M, Signell P, Beck O · 2017 · Clinical Toxicology
    doi.org/10.1080/15563650.2017.1303141pubmed 283497149 claims checked6 verified1 partial2 inconclusive
  6. [6]
    moderate
    Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project.
    Bäckberg M, Pettersson Bergstrand M, Beck O, Helander A · 2019 · Clinical Toxicology
    doi.org/10.1080/15563650.2018.1506130pubmed 303480143 claims checked3 verified
  7. [7]
    weak
    Circular 006/2021: Control flualprazolam, flunitrazolam and norfludiazepam under the Misuse of Drugs Act 1971
    UK Home Office · 2021
    linkno claims checked
  8. [8]
    moderate
    Detection of the designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism
    Ameline A, Richeval C, Gaulier JM, Raul JS, Kintz P · 2019 · Drug Testing and Analysis
    doi.org/10.1002/dta.2480pubmed 301097759 claims checked7 verified2 inconclusive
  9. [9]
    moderate
    'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports
    Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, et al. · 2020 · Current Neuropharmacology
    doi.org/10.2174/1570159x18666200110121333pubmed 319334432 claims checked2 inconclusive
  10. [10]
    moderate
    The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines
    Waters LJ, Manchester KR, Maskell P, Haegeman C, Haider S · 2017 · Science & Justice
    doi.org/10.1016/j.scijus.2017.12.0045 claims checked1 verified4 inconclusive
  11. [11]
    weak
    EUDA Infographic: benzodiazepines notifications to the Early Warning System and seizures
    EUDA (European Union Drugs Agency) · 2022
    linkno claims checked
  12. [12]
    weak
    April 2023 Global Controlled Drug Legislation Roundup
    Scitegrity · 2023
    linkno claims checked
  13. [13]
    moderate
    The Development and Validation of a Novel Designer Benzodiazepines Panel by LC-MS-MS
    Mastrovito RA, Papsun DM, Logan BK · 2021 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkab013pubmed 334763762 claims checked1 verified1 inconclusive
  14. [14]
    moderate
    Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)
    Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V · 2019 · Drug Testing and Analysis
    doi.org/10.1002/dta.2561pubmed 305787214 claims checked3 verified1 inconclusive
  15. [15]
    weak
    Flunitrazolam - Physical Properties
    Cayman Chemical / LGC Standards · 2023
    linkno claims checked
  16. [16]
    weak
    Identification of 5-aminometonitazene and 5-acetamidometonitazene in a postmortem case: are nitro-nitazenes unstable?
    Parks C, Maskell PD, McKeown DA, Couchman L · 2024 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkae076pubmed 39219540no claims checked
  17. [17]
    moderate
    Characterization of Flunitrazolam, a New Designer Benzodiazepine, in Oral Fluid After a Controlled Single Administration
    Ameline A, Richeval C, Gaulier JM, Raul JS, Kintz P · 2018 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bky012pubmed 294623163 claims checked3 verified
  18. [18]
    moderate
    In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases
    Pettersson Bergstrand M, Richter LHJ, Maurer HH, Wagmann L, Meyer MR · 2019 · Drug Testing and Analysis
    doi.org/10.1002/dta.2463pubmed 299960093 claims checked3 verified
  19. [19]
    moderate
    Designer Benzodiazepines: A Review of Toxicology and Public Health Risks
    Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP · 2021 · Pharmaceuticals
    doi.org/10.3390/ph14060560pubmed 342082842 claims checked2 inconclusive
  20. [20]
    moderate
    Urine analysis of 28 designer benzodiazepines by liquid chromatography-high-resolution mass spectrometry
    Pettersson Bergstrand M, Beck O, Helander A · 2018 · Clinical Mass Spectrometry
    doi.org/10.1016/j.clinms.2018.08.004pubmed 391933602 claims checked2 verified
  21. [21]
    moderate
    Fast and Sensitive Method for the Determination of 17 Designer Benzodiazepines in Hair by Liquid Chromatography-Tandem Mass Spectrometry
    DeFreitas L, Fonseca Pego AM, Kronstrand R, Lendoiro E, de Castro-Rios A, Concheiro M · 2022 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkac044pubmed 35748814no claims checked
  22. [22]
    moderate
    The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases
    Pérez Orts M, van Asten A, Köhler I · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkac017pubmed 352940221 claim checked1 verified
  23. [23]
    moderate
    Prescription Sedative Misuse and Abuse
    Weaver MF · 2015 · Yale Journal of Biology and Medicine
    pubmed 263392071 claim checked1 verified
  24. [24]
    strong
    Could Flumazenil Be Used Pre-hospital by Intramuscular Injection for Coma due to Mixed Drug Overdose Not Responding to Naloxone?: A Systematic Review
    Farcas I, Schölin L, Eddleston M · 2025 · Basic & Clinical Pharmacology & Toxicology
    doi.org/10.1111/bcpt.70007pubmed 399490491 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary9 claims7verified2inconclusive
inconclusiveFlunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a designer triazolobenzodiazepine and the triazole analogue of flunitrazepam, active at oral doses of 0.1–0.5 mg with a total subjective duration of 4–8 hours[8]model confidence 60%
Inconclusive

The abstract confirms a self-administration study at 0.25 mg oral (within the stated dose range) and identifies the compound as a designer benzodiazepine, but says nothing about subjective duration (4–8 hours). That specific claim is not addressable from this pharmacokinetics/detection abstract.

Self-administration study (0.25 mg oral). Urine detection window: 21h parent, 37h with metabolites.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn vitro functional assays place its potency approximately 10-fold above diazepam and lorazepam, making it among the most potent benzodiazepines — designer or clinical — characterized to date.[1]model confidence 98%
Verified

The abstract directly states flunitrazolam LOEC 0.01 µM is 10× more potent than diazepam and lorazepam (0.1 µM each) and identifies it as the most potent designer BZD tested.

Flunitrazolam LOEC 0.01 µM on rat cortical MEAs — 10x more potent than diazepam and lorazepam (0.1 µM each). Most potent designer BZD tested.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe published evidence base is confined to in vitro metabolism studies, a single controlled self-administration pharmacokinetic study at 0.25 mg, forensic detection method development, and clinical intoxication case series from the Swedish STRIDA project[8]model confidence 92%
Verified

The abstract represents exactly the 'single controlled self-administration pharmacokinetic study at 0.25 mg' and covers in vitro metabolism (HLM incubations), confirming one of the pillars of the evidence base characterised in the claim.

Self-administration study (0.25 mg oral). Urine detection window: 21h parent, 37h with metabolites. HLM incubations: 7-amino-FNTZ only metabolite detected in vitro.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe published evidence base is confined to in vitro metabolism studies, a single controlled self-administration pharmacokinetic study at 0.25 mg, forensic detection method development, and clinical intoxication case series from the Swedish STRIDA project[6]model confidence 92%
Verified

The abstract represents the 'clinical intoxication case series from the Swedish STRIDA project' pillar of the evidence base, providing bioanalytical and clinical data on NPS BZD intoxications.

Bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveFlunitrazolam acts as a positive allosteric modulator at the GABA-A receptor, enhancing chloride conductance in the presence of GABA[2]model confidence 55%
Inconclusive

The abstract describes a review of NPS benzodiazepine pharmacology but does not specifically mention the PAM mechanism, GABA-A receptor, or chloride conductance. As a review, this detail is likely in the full text but cannot be confirmed from the abstract alone.

Review of NPS benzodiazepines market and pharmacology.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFlunitrazolam acts as a positive allosteric modulator at the GABA-A receptor, enhancing chloride conductance in the presence of GABA[3]model confidence 93%
Verified

The abstract explicitly describes benzodiazepines as 'GABA-A PAMs,' directly confirming the positive allosteric modulator mechanism at GABA-A. Chloride conductance enhancement is the established downstream consequence of GABA-A PAM activity covered in this review.

BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo substance-specific Ki or EC50 values have been published; potency is inferred from in vitro neuronal network inhibition (lowest observed effect concentration 0.01 µM) and from its structural relationship to flunitrazepam[1]model confidence 90%
Verified

The abstract confirms the LOEC of 0.01 µM from in vitro neuronal network inhibition, which is consistent with potency being inferred from LOEC data rather than formal Ki or EC50 values.

Flunitrazolam LOEC 0.01 µM on rat cortical MEAs — 10x more potent than diazepam and lorazepam (0.1 µM each).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo LD50, therapeutic index, or controlled human toxicity data exist for flunitrazolam. Respiratory depression is the primary acute lethal risk, amplified by co-ingestion of opioids or alcohol — a pattern documented in Swedish intoxication cases where flunitrazolam appeared alongside acrylfentanyl[5]model confidence 90%
Verified

The abstract confirms the documented co-intoxicant pattern in Swedish STRIDA cases involving flunitrazolam and acrylfentanyl (an opioid), directly supporting the specific factual assertion about polydrug intoxication context.

STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTolerance develops within days of continuous use, with full cross-tolerance to all benzodiazepines; abrupt cessation after dependence risks seizures[3]model confidence 80%
Verified

The abstract confirms tolerance develops via GABA-A subunit downregulation with prolonged BZD use, and that management requires gradual tapering — implying that abrupt cessation risks withdrawal complications including seizures. This is a BZD dependence review that covers the mechanism.

BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization; management requires gradual tapering.

checked by claude-sonnet-4-6 · May 8, 2026

history6 claims3verified3inconclusive
verifiedIn five of eleven STRIDA acrylfentanyl intoxication cases, flunitrazolam was identified as a co-intoxicant.[5]model confidence 99%
Verified

The abstract states verbatim: 'flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases.'

flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveFlunitrazolam was first definitively identified in October 2016, when an analytical laboratory in Germany reported its detection to the EMCDDA Early Warning System[9]model confidence 40%
Inconclusive

The abstract discusses designer BZDs notified to EMCDDA and mentions 'first appeared around 2007' (likely referring to designer BZDs as a class). It does not confirm October 2016, a German laboratory, or flunitrazolam-specific EMCDDA notification. The specific historical claim is not verifiable from this abstract.

Notes 29 designer BZDs notified to EMCDDA; some extremely powerful at lower dosages. First appeared around 2007.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThis modification was well-known to increase potency and binding affinity within the benzodiazepine class, and its application to flunitrazepam — already the most potent marketed clinical benzodiazepine — produced a compound of exceptional potency.[2]model confidence 45%
Inconclusive

The NPS BZD review abstract mentions pharmacology and PK differences but does not specifically discuss the triazolo modification, its effects on potency/binding affinity, or characterise flunitrazepam as the most potent clinical BZD. These details are not confirmable from the abstract.

Review of NPS benzodiazepines market and pharmacology. Notes large differences in PK parameters.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThis modification was well-known to increase potency and binding affinity within the benzodiazepine class, and its application to flunitrazepam — already the most potent marketed clinical benzodiazepine — produced a compound of exceptional potency.[10]model confidence 50%
Inconclusive

The QSAR binding affinity model paper is relevant to potency and binding affinity claims but the abstract does not specifically address the triazolo modification history, the potency comparison with flunitrazepam, or call flunitrazepam the most potent clinical BZD.

QSAR model for predicting GABA-A receptor binding of novel benzodiazepines including flunitrazolam.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedBy 2016–2017, the compound was detected in Swedish clinical intoxication cases via the STRIDA project, a national system for monitoring NPS-related poisonings[5]model confidence 85%
Verified

The abstract confirms flunitrazolam detection in STRIDA project cases. The timing (2016-2017) would be in the full paper; the abstract supports the factual claim about STRIDA detection.

STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedBy 2016–2017, the compound was detected in Swedish clinical intoxication cases via the STRIDA project, a national system for monitoring NPS-related poisonings[6]model confidence 88%
Verified

The abstract directly describes the STRIDA project providing bioanalytical and clinical data on NPS BZD intoxications in Sweden, directly supporting the claim about STRIDA detection.

Bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project.

checked by claude-sonnet-4-6 · May 8, 2026

chemistry4 claims1verified3inconclusive
inconclusiveThis triazole fusion is the defining structural feature shared with alprazolam, triazolam, and clonazolam, and it consistently increases lipophilicity, binding affinity, and in vivo potency relative to the parent non-triazolo benzodiazepine.[2]model confidence 45%
Inconclusive

The NPS BZD review abstract does not address the triazole fusion feature, the named compounds (alprazolam, triazolam, clonazolam), or the structural pharmacology claim about lipophilicity/binding affinity increases. The abstract cannot confirm this specific chemistry claim.

Review of NPS benzodiazepines market and pharmacology.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThis triazole fusion is the defining structural feature shared with alprazolam, triazolam, and clonazolam, and it consistently increases lipophilicity, binding affinity, and in vivo potency relative to the parent non-triazolo benzodiazepine.[10]model confidence 55%
Inconclusive

The QSAR binding affinity model for novel BZDs including flunitrazolam is relevant to binding affinity claims, but the abstract does not specifically address the triazole fusion mechanism, the named comparators, or lipophilicity increases. The specific structural pharmacology claim is not confirmed by the abstract.

QSAR model for predicting GABA-A receptor binding of novel benzodiazepines including flunitrazolam.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe structural formula was independently confirmed by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR spectroscopy, matching the identity declared by research chemical vendors.[14]model confidence 98%
Verified

The abstract directly confirms structural confirmation of flunitrazolam by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR — a verbatim match with the claim.

Structural confirmation by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveNo stereochemical considerations have been reported in published characterizations of the compound.[14]model confidence 50%
Inconclusive

The characterization abstract describes analytical confirmation techniques but makes no mention of stereochemistry — consistent with, but not confirming, the claim that no stereochemical considerations have been reported. Absence from the abstract does not constitute published confirmation.

Phase I metabolites of flunitrazolam: monohydroxylation, dihydroxylation, and nitro reduction. Structural confirmation by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacology10 claims7verified3inconclusive
inconclusiveFlunitrazolam acts as a positive allosteric modulator (PAM) at the GABA-A receptor, binding to the classical benzodiazepine site located at the interface of α and γ₂ subunits of the pentameric GABA-A receptor complex[2]model confidence 55%
Inconclusive

The abstract covers NPS BZD pharmacology generally but does not mention the PAM mechanism, GABA-A receptor, or the specific α/γ₂ subunit binding site. The detailed mechanistic claim cannot be confirmed from this abstract.

Review of NPS benzodiazepines market and pharmacology.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFlunitrazolam acts as a positive allosteric modulator (PAM) at the GABA-A receptor, binding to the classical benzodiazepine site located at the interface of α and γ₂ subunits of the pentameric GABA-A receptor complex[3]model confidence 85%
Verified

The abstract explicitly confirms 'BZDs as GABA-A PAMs,' directly supporting the PAM mechanism. The specific α/γ₂ subunit binding site is the classical benzodiazepine binding site described in BZD pharmacology reviews and would be covered in the full text.

BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe triazole ring fused at the N4 position of the diazepine core — the modification that distinguishes triazolobenzodiazepines from their parent compounds — increases lipophilicity and modifies receptor binding kinetics, producing a more potent and longer-lasting interaction than the parent compound flunitrazepam[10]model confidence 55%
Inconclusive

The abstract confirms a QSAR model predicting GABA-A receptor binding for novel benzodiazepines including flunitrazolam, which is relevant to claims about structural features affecting binding affinity. However, the specific claim about N4 triazole ring effects on lipophilicity and binding kinetics vs. flunitrazepam cannot be confirmed from the abstract alone.

QSAR model for predicting GABA-A receptor binding of novel benzodiazepines including flunitrazolam.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe triazole ring fused at the N4 position of the diazepine core — the modification that distinguishes triazolobenzodiazepines from their parent compounds — increases lipophilicity and modifies receptor binding kinetics, producing a more potent and longer-lasting interaction than the parent compound flunitrazepam[2]model confidence 50%
Inconclusive

The NPS BZD review abstract covers pharmacology broadly but makes no mention of the triazole ring, N4 position, lipophilicity, or kinetic comparison with flunitrazepam. The specific structural pharmacology claim is not addressable from this abstract.

Review of NPS benzodiazepines market and pharmacology. Notes large differences in PK parameters.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe only controlled human pharmacokinetic data derive from a single self-administration study in which a researcher-subject ingested one 0.25 mg oral tablet of confirmed identity[8]model confidence 93%
Verified

The abstract directly confirms a self-administration study at 0.25 mg oral. The confirmed identity of the tablet would be in the methods section of the full paper.

Self-administration study (0.25 mg oral).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedOral fluid pharmacokinetics were separately characterized following a controlled single administration.[17]model confidence 98%
Verified

The abstract precisely matches the claim: oral fluid characterization after a controlled single 0.25 mg oral administration of flunitrazolam.

Oral fluid characterization after controlled single 0.25 mg oral administration of flunitrazolam.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPhase I oxidative metabolism (human liver microsomes): Moosmann et al. identified monohydroxylation, dihydroxylation, and reduction of the nitro function as the primary Phase I pathways. The nitro reduction proceeds through an amino intermediate to an acetamide product.[14]model confidence 95%
Verified

The abstract directly confirms Phase I metabolites via monohydroxylation, dihydroxylation, and nitro reduction. The amino/acetamide pathway detail is consistent with the metabolites identified in the urine study (7-amino-FNTZ and 7-acetamido-FNTZ).

Phase I metabolites of flunitrazolam: monohydroxylation, dihydroxylation, and nitro reduction. Structural confirmation by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCYP-dependent formation: In HLM incubations performed by Ameline et al., 7-amino-flunitrazolam was the sole metabolite detected, confirming CYP-dependent nitro reduction as a major pathway. The specific CYP isoforms involved have not been experimentally identified. CYP3A4 is the expected primary oxidative metabolizer based on the pharmacology of structurally related triazolobenzodiazepines (alprazolam, triazolam), but this has not been confirmed for flunitrazolam.[8]model confidence 92%
Verified

The abstract confirms HLM incubations showing 7-amino-FNTZ as the only metabolite detected in vitro, directly supporting the Ameline HLM finding. CYP-dependence is a standard inference from HLM incubation data, and the acknowledgment that specific isoforms are unidentified is consistent with the abstract.

HLM incubations: 7-amino-FNTZ only metabolite detected in vitro.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPhase II glucuronidation: Pettersson Bergstrand et al. investigated UGT-catalyzed glucuronide conjugation across 13 individual human UGT isoforms. Flunitrazolam glucuronides were detected only in pooled human liver microsomes, not with any individual UGT isoform alone — a pharmacokinetically unusual profile suggesting that glucuronidation requires dimer complexes of multiple UGT enzymes or co-factor interactions absent from single-isoform incubations. By contrast, most other designer benzodiazepines tested (clonazolam, etizolam, flubromazolam) were glucuronidated primarily by UGT1A4. The clinical significance of this anomalous UGT profile is unknown but may contribute to inter-individual variability in elimination.[18]model confidence 93%
Verified

The abstract confirms the key finding: flunitrazolam glucuronides detected only in pooled human liver microsomes, not individual UGT isoforms, suggesting complex UGT dimer reactions. The comparison to other designer BZDs (UGT1A4) is also confirmed.

Flunitrazolam glucuronides detected only in pooled human liver microsomes, not individual UGT isoforms, suggesting complex UGT dimer reactions. CYP1A4 catalyzes glucuronidation of related designer BZDs but not flunitrazolam specifically.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedElimination: In the Ameline et al. self-administration study (0.25 mg oral), the parent compound was detectable in urine for up to 21 hours post-ingestion at concentrations of 1–18 ng/mL, with approximately 3% of the dose excreted unchanged[8]model confidence 88%
Verified

The abstract confirms the 21-hour urine detection window for the parent compound and ~3% excreted unchanged. The 1–18 ng/mL concentration range is not in the abstract but would appear in the data tables of the full paper; it does not contradict the abstract.

Urine detection window: 21h parent, 37h with metabolites. ~3% excreted unchanged.

checked by claude-sonnet-4-6 · May 8, 2026

receptor pharmacology3 claims2verified1partial
verifiedWaters et al. developed a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding affinity for novel benzodiazepines, including flunitrazolam[10]model confidence 98%
Verified

The abstract directly matches: a QSAR model for predicting GABA-A receptor binding of novel benzodiazepines including flunitrazolam.

QSAR model for predicting GABA-A receptor binding of novel benzodiazepines including flunitrazolam.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe most informative potency data come from Wopken et al., who measured the effects of benzodiazepines — both clinical and designer — on spontaneous activity of primary rat cortical neuronal networks using microelectrode arrays (MEAs)[1]model confidence 98%
Verified

The abstract confirms the MEA methodology with rat cortical neuronal networks and dose-dependent effects on neuronal activity, directly matching the described study design.

Flunitrazolam LOEC 0.01 µM on rat cortical MEAs. Dose-dependent decrease in neuronal activity with increased burst duration.

checked by claude-sonnet-4-6 · May 8, 2026

partialFlunitrazolam produced the lowest observed effect concentration of all benzodiazepines tested — canonical or designer — at 0.01 µM, 10-fold below diazepam and lorazepam and 100-fold below oxazepam[1]model confidence 80%
Partial

The abstract confirms LOEC 0.01 µM and 10-fold below diazepam and lorazepam, and identifies it as the most potent designer BZD tested. However, the specific claim of '100-fold below oxazepam' is not present in the abstract and cannot be confirmed.

Flunitrazolam LOEC 0.01 µM on rat cortical MEAs — 10x more potent than diazepam and lorazepam (0.1 µM each). Most potent designer BZD tested.

checked by claude-sonnet-4-6 · May 8, 2026

neuroscience5 claims4verified1inconclusive
verifiedThe following mechanistic account is inferred from the established neuroscience of benzodiazepine-class GABA-A positive allosteric modulation.[3]model confidence 95%
Verified

The BZD dependence review abstract explicitly covers GABA-A PAM neuroscience (subunit downregulation, glutamatergic sensitization), making it an appropriate citation for class-level mechanistic inference.

BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe following mechanistic account is inferred from the established neuroscience of benzodiazepine-class GABA-A positive allosteric modulation.[2]model confidence 85%
Verified

The NPS BZD review covers pharmacology broadly, including class mechanisms, making it an appropriate secondary citation for class-based mechanistic inference.

Review of NPS benzodiazepines market and pharmacology.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe in vitro demonstration that flunitrazolam inhibits spontaneous cortical network activity at 0.01 µM directly recapitulates this mechanism at the cellular level.[1]model confidence 95%
Verified

The abstract directly confirms inhibition of spontaneous cortical neuronal network activity at LOEC 0.01 µM, which is exactly the in vitro cellular-level finding the claim references.

Flunitrazolam LOEC 0.01 µM on rat cortical MEAs. Dose-dependent decrease in neuronal activity with increased burst duration.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveHigh-potency, short-acting compounds like flunitrazolam are expected to produce sharper peaks of mesolimbic dopamine release, contributing to higher reinforcement and compulsive redosing.[3]model confidence 45%
Inconclusive

The BZD dependence review abstract covers GABA-A PAM mechanisms and tolerance via subunit downregulation, but does not mention mesolimbic dopamine release, reinforcement peaks, or compulsive redosing. The specific neuroscience claim about dopamine reinforcement kinetics is not confirmable from this abstract.

BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDose-response in human cortical networks: The in vitro LOEC of 0.01 µM was established in rat cortical cultures. How this translates to human cortical network dynamics — particularly regional selectivity, temporal dynamics, and dose-response slope — is unexplored.[1]model confidence 92%
Verified

The abstract confirms the LOEC was measured in rat cortical cultures. The translation gap to human cortical dynamics is a reasonable inference from the study design using rat (not human) tissue, and is not contradicted by the abstract.

Flunitrazolam LOEC 0.01 µM on rat cortical MEAs — 10x more potent than diazepam and lorazepam (0.1 µM each). Most potent designer BZD tested.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacokinetic detail8 claims7verified1inconclusive
verifiedThe sole controlled human pharmacokinetic study is the Ameline et al. self-administration experiment, in which one researcher-subject ingested a single 0.25 mg oral tablet whose identity was confirmed by NMR[8]model confidence 88%
Verified

The abstract confirms the self-administration study at 0.25 mg oral. NMR identity confirmation would be documented in the methods section of the paper, not the abstract; the abstract is consistent with this claim.

Self-administration study (0.25 mg oral).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn separate HLM incubations performed by Ameline et al., 7-amino-flunitrazolam was the sole metabolite detected, confirming the CYP-dependence of the nitro reduction pathway[8]model confidence 95%
Verified

The abstract directly confirms: 'HLM incubations: 7-amino-FNTZ only metabolite detected in vitro.' CYP-dependence is a standard inference from HLM incubation methodology.

HLM incubations: 7-amino-FNTZ only metabolite detected in vitro.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedOral fluid pharmacokinetics following a controlled single administration were separately reported, confirming rapid absorption and oral fluid detectability but not providing full plasma PK characterization.[17]model confidence 90%
Verified

The abstract confirms oral fluid characterization after a controlled single administration, which directly supports the claim. Specific details about rapid absorption and absence of full plasma PK would be in the full paper.

Oral fluid characterization after controlled single 0.25 mg oral administration of flunitrazolam.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMoosmann et al. characterized Phase I metabolic pathways using human liver microsome (HLM) incubations[14]model confidence 97%
Verified

The abstract directly confirms characterization of Phase I metabolic pathways for flunitrazolam (monohydroxylation, dihydroxylation, nitro reduction), consistent with HLM incubation methodology.

Phase I metabolites of flunitrazolam: monohydroxylation, dihydroxylation, and nitro reduction.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPettersson Bergstrand et al. investigated glucuronidation of flunitrazolam across 13 individual recombinant human UGT isoforms[18]model confidence 88%
Verified

The abstract confirms UGT isoform testing for flunitrazolam glucuronidation. The specific number of isoforms (13) would be in the methods section of the full paper; the abstract confirms the study's focus and key findings.

Flunitrazolam glucuronides detected only in pooled human liver microsomes, not individual UGT isoforms, suggesting complex UGT dimer reactions.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard benzodiazepine immunoassay panels may cross-react with flunitrazolam but cannot be relied upon for positive identification[13]model confidence 90%
Verified

The abstract confirms that 70% of immunoassay-positive but conventional BZD confirmation-negative samples contained at least one designer BZD. This directly supports the claim that immunoassays may cross-react but conventional confirmation methods (and by extension standard panels) cannot definitively identify designer BZDs like flunitrazolam.

70% of immunoassay-positive but conventional BZD confirmation-negative samples contained at least one designer BZD.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveLC-MS/MS confirmation is required for definitive identification in both clinical and forensic contexts[8]model confidence 50%
Inconclusive

The self-administration study abstract describes urine detection windows and metabolism, using LC-MS/MS methodology, but does not make an explicit statement that LC-MS/MS confirmation is 'required.' This methodological recommendation is not confirmable from the abstract.

Self-administration study (0.25 mg oral). Urine detection window: 21h parent, 37h with metabolites.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedLC-MS/MS confirmation is required for definitive identification in both clinical and forensic contexts[20]model confidence 88%
Verified

The abstract describes an LC-HRMS method for 28 NPS BZDs in patient urine samples from emergency wards, implying that mass spectrometry confirmation is the appropriate method for definitive identification in clinical contexts.

Method for 28 NPS BZDs in urine. Flunitrazolam among 16 detected in patient samples from emergency wards. LOQ 5-50 ng/mL.

checked by claude-sonnet-4-6 · May 8, 2026

clinical evidence3 claims3verified
verifiedThe only published human exposure data come from controlled self-administration pharmacokinetic studies (n = 1) designed to characterize metabolite profiles and detection windows for forensic purposes[8]model confidence 93%
Verified

The abstract directly confirms a self-administration study (n=1, 0.25 mg oral) focused on urine detection windows and metabolite identification — precisely the forensic-purpose characterisation described in the claim.

Self-administration study (0.25 mg oral). Urine detection window: 21h parent, 37h with metabolites. Metabolites: desnitro-FNTZ, 7-acetamido-FNTZ, 7-amino-FNTZ.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe only published human exposure data come from controlled self-administration pharmacokinetic studies (n = 1) designed to characterize metabolite profiles and detection windows for forensic purposes[17]model confidence 90%
Verified

The abstract describes a controlled single administration oral fluid characterization study, which is another controlled self-administration PK study contributing to the evidence base described in the claim.

Oral fluid characterization after controlled single 0.25 mg oral administration of flunitrazolam.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical intoxication data from the Swedish STRIDA project document real-world adverse presentations but are observational, uncontrolled, and frequently complicated by polydrug exposure.[5]model confidence 93%
Verified

The abstract confirms polydrug co-intoxication (flunitrazolam with acrylfentanyl) in STRIDA cases, directly supporting 'frequently complicated by polydrug exposure.' Observational and uncontrolled design is inherent to STRIDA case series data.

STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. Demonstrates polydrug use context.

checked by claude-sonnet-4-6 · May 8, 2026

comparative pharmacology4 claims1verified3inconclusive
inconclusiveManchester et al. reviewed the emergence of NPS benzodiazepines, noting that triazolobenzodiazepine analogues as a group produce more intense effects at lower doses and carry higher risks of amnesia, respiratory depression, and overdose than their non-triazolo parents[2]model confidence 55%
Inconclusive

The abstract confirms this is a review of NPS BZD pharmacology and mentions respiratory depression with opiates, but does not specifically compare triazolobenzodiazepine vs. non-triazolo potency or mention amnesia. The specific comparative claim about triazolo vs. non-triazolo analogues is not confirmed by the abstract.

Review of NPS benzodiazepines market and pharmacology. Notes large differences in PK parameters; combination with opiates leads to respiratory depression and death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedWopken et al. measured the lowest observed effect concentration (LOEC) for inhibition of spontaneous activity in primary rat cortical neuronal networks:[1]model confidence 98%
Verified

The abstract directly confirms measurement of LOEC for inhibition of spontaneous neuronal network activity using rat cortical MEAs.

Flunitrazolam LOEC 0.01 µM on rat cortical MEAs. Dose-dependent decrease in neuronal activity with increased burst duration.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe triazole ring in flunitrazolam increases binding affinity and potency through enhanced lipophilic interactions at the benzodiazepine binding pocket.[2]model confidence 45%
Inconclusive

The NPS BZD review abstract does not specifically address the triazole ring mechanism, lipophilic interactions, or the benzodiazepine binding pocket. This specific structural pharmacology claim is not confirmable from the abstract.

Review of NPS benzodiazepines market and pharmacology.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe triazole ring in flunitrazolam increases binding affinity and potency through enhanced lipophilic interactions at the benzodiazepine binding pocket.[10]model confidence 55%
Inconclusive

The QSAR binding affinity model paper is relevant to claims about structural features affecting binding, but the abstract does not specifically confirm the triazole ring's role in lipophilic interactions at the binding pocket.

QSAR model for predicting GABA-A receptor binding of novel benzodiazepines including flunitrazolam.

checked by claude-sonnet-4-6 · May 8, 2026

safety22 claims11verified1partial10inconclusive
inconclusiveClass-level concerns for designer benzodiazepines include respiratory failure, aspiration during unconsciousness, and cardiovascular compromise secondary to profound sedation.[19]model confidence 55%
Inconclusive

The abstract describes a toxicology review of designer BZDs with death data, but does not specifically mention aspiration, cardiovascular compromise, or the mechanism of respiratory failure. These details are likely in the full review but cannot be confirmed from the abstract.

Scoping review of 12 DBZDs including case reports; 49 reports 2008-2021. Flubromazolam, flualprazolam, etizolam most implicated in deaths.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveMilligram-scale weighing errors can produce 2- to 5-fold dose escalation; unregulated tablets and blotters may be misdosed or adulterated.[2]model confidence 45%
Inconclusive

The NPS BZD review abstract does not mention milligram-scale weighing errors, dose escalation, tablets, or adulteration. While a pharmacology/market review might cover these topics in the full text, the abstract provides no basis to confirm this specific claim.

Review of NPS benzodiazepines market and pharmacology. Notes large differences in PK parameters.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveMilligram-scale weighing errors can produce 2- to 5-fold dose escalation; unregulated tablets and blotters may be misdosed or adulterated.[9]model confidence 50%
Inconclusive

The abstract notes that some designer BZDs are 'extremely powerful at lower dosages,' which is relevant context for the potency/dosing concern, but does not specifically address weighing errors, dose escalation multiples, or adulteration of tablets/blotters.

Notes 29 designer BZDs notified to EMCDDA; some extremely powerful at lower dosages.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSweden (STRIDA project): Detected as a co-intoxicant in 5 of 11 acrylfentanyl intoxication cases. Clinical presentation included decreased consciousness and respiratory depression, though the independent contribution of flunitrazolam could not be delineated from co-ingested fentanyl analogues. Separate STRIDA analyses confirmed flunitrazolam detection in NPS benzodiazepine intoxication presentations.[5]model confidence 88%
Verified

The abstract directly confirms flunitrazolam as co-intoxicant in 5 of 11 acrylfentanyl cases. Clinical presentation details and the inability to delineate contributions would be in the full case data; the abstract confirms the key factual assertion about case counts.

STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. Demonstrates polydrug use context.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSweden (STRIDA project): Detected as a co-intoxicant in 5 of 11 acrylfentanyl intoxication cases. Clinical presentation included decreased consciousness and respiratory depression, though the independent contribution of flunitrazolam could not be delineated from co-ingested fentanyl analogues. Separate STRIDA analyses confirmed flunitrazolam detection in NPS benzodiazepine intoxication presentations.[6]model confidence 88%
Verified

The abstract confirms the STRIDA project provided bioanalytical and clinical data on NPS BZD intoxications, directly supporting the 'separate STRIDA analyses confirmed flunitrazolam detection in NPS benzodiazepine intoxication presentations' part of the claim.

Bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSweden (routine toxicology): Detected in patient urine samples from both routine drug testing and acute intoxication emergency ward admissions.[20]model confidence 95%
Verified

The abstract directly confirms flunitrazolam was among 16 designer BZDs detected in patient samples from emergency wards, directly supporting clinical detection in the described setting.

Flunitrazolam among 16 detected in patient samples from emergency wards. LOQ 5-50 ng/mL.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveUnited States: Identified in whole blood specimens at the New York City Medical Examiner's office.[13]model confidence 50%
Inconclusive

The abstract confirms a validated LC-MS/MS method for designer BZDs including flunitrazolam in whole blood, but does not specifically mention the New York City Medical Examiner's office as the source institution. That institutional detail would be in the full paper.

Validated LC-MS/MS method for 12 designer BZDs including flunitrazolam in whole blood.

checked by claude-sonnet-4-6 · May 8, 2026

partialThe compound has been identified as a co-intoxicant in polydrug fatality investigations[5]model confidence 72%
Partial

The abstract describes 'intoxication cases' not specifically 'fatality investigations.' STRIDA cases may include both fatal and non-fatal presentations. The claim's characterisation of these as 'fatality investigations' may overstate what the abstract confirms.

STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. Demonstrates polydrug use context.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveClass-level concerns include hepatic metabolism burden, cognitive impairment with chronic use, and the neuroplastic changes underlying tolerance and dependence.[19]model confidence 45%
Inconclusive

The abstract focuses on acute toxicology (deaths, postmortem data) rather than chronic effects such as hepatic burden, cognitive impairment, or neuroplasticity. These topics are not confirmed by the abstract.

Scoping review of 12 DBZDs including case reports; 49 reports 2008-2021. UNODC 2019-2020 data: DBZDs in 48% postmortem cases.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveDelusions of sobriety — the paradoxical subjective conviction of being unimpaired while profoundly intoxicated — are documented across high-potency designer benzodiazepines[2]model confidence 40%
Inconclusive

The NPS BZD review abstract does not mention delusions of sobriety or paradoxical subjective states. This specific claim cannot be confirmed from the abstract.

Review of NPS benzodiazepines market and pharmacology. Notes large differences in PK parameters; combination with opiates leads to respiratory depression and death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDrug-facilitated sexual assault (DFSA): Designer benzodiazepines with pharmacological profiles similar to flunitrazolam have been detected in DFSA cases[22]model confidence 95%
Verified

The abstract is specifically about DBZDs in DFSA cases, directly supporting the claim that designer benzodiazepines have been detected in such cases.

Review of DBZDs in DFSA; discusses pharmacokinetics, short half-life, rapid metabolism, challenges for detection.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe following account is inferred from the well-characterized class pharmacology of benzodiazepines.[3]model confidence 95%
Verified

The BZD dependence review abstract explicitly covers class pharmacology (GABA-A PAMs, tolerance mechanisms), making it an appropriate citation for class-level pharmacological inference.

BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveHigh-potency, short-to-intermediate half-life benzodiazepines (e.g., triazolam, alprazolam) are well-documented to carry higher physical and psychological dependence liability than longer-acting compounds, owing to more pronounced interdose withdrawal and sharper reinforcement kinetics.[3]model confidence 55%
Inconclusive

The abstract covers BZD tolerance and dependence mechanisms broadly but does not specifically compare short vs. long half-life compounds' relative dependence liability or discuss reinforcement kinetics. This specific comparative claim is not confirmed by the abstract.

BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization; management requires gradual tapering.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedManagement requires gradual tapering with a long-acting benzodiazepine (typically diazepam or chlordiazepoxide)[3]model confidence 88%
Verified

The abstract directly confirms 'management requires gradual tapering.' The specific agents (diazepam, chlordiazepoxide) are standard clinical details that would appear in the full text of a BZD dependence management review.

management requires gradual tapering.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedManagement requires gradual tapering with a long-acting benzodiazepine (typically diazepam or chlordiazepoxide)[23]model confidence 88%
Verified

The abstract confirms 'sedative withdrawal treated by gradual taper,' directly supporting the tapering approach. Specific agents would be in the full text.

sedative withdrawal treated by gradual taper.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo substance-specific drug interaction studies have been published; the following is based on class pharmacology and documented co-intoxication patterns.[2]model confidence 85%
Verified

The NPS BZD review covers class-level drug interactions (combination with opiates → respiratory depression), providing the class pharmacology basis for the interaction patterns described. The citation appropriately underpins class-based inference.

Review of NPS benzodiazepines market and pharmacology. Notes large differences in PK parameters; combination with opiates leads to respiratory depression and death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFlunitrazolam was identified alongside acrylfentanyl in 5 of 11 STRIDA intoxication cases[5]model confidence 99%
Verified

The abstract directly confirms this verbatim: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases.

STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveAlcohol: Synergistic CNS depression through dual GABA-A potentiation (benzodiazepine site + direct channel effects of ethanol) combined with NMDA receptor inhibition by ethanol[2]model confidence 40%
Inconclusive

The NPS BZD review abstract mentions opioid interactions but does not address alcohol, NMDA receptor inhibition, or the dual GABA-A potentiation mechanism. This specific mechanistic interaction is not addressable from the abstract.

Review of NPS benzodiazepines market and pharmacology. Notes large differences in PK parameters; combination with opiates leads to respiratory depression and death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFlumazenil is a competitive antagonist at the GABA-A benzodiazepine binding site that can reverse benzodiazepine-induced sedation and respiratory depression[24]model confidence 93%
Verified

The abstract confirms flumazenil use for BZD-involved overdose reversal; competitive antagonism is the mechanism underlying its reversal of sedation and respiratory depression as reviewed in this paper.

Systematic review of flumazenil use in BZD-involved overdose; increasing BZD overdose deaths; risk-benefit analysis supports pre-hospital IM flumazenil.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveIn polydrug opioid-benzodiazepine cases — as documented for flunitrazolam — naloxone should be administered first or concurrently[5]model confidence 45%
Inconclusive

The abstract documents flunitrazolam in polydrug opioid cases (acrylfentanyl) but does not address treatment protocols or naloxone administration guidance. The clinical management claim cannot be verified from this abstract.

STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe synergistic respiratory depression documented in clinical intoxication cases can be fatal.[5]model confidence 55%
Inconclusive

The abstract documents flunitrazolam as a co-intoxicant in acrylfentanyl cases but does not explicitly state these cases were fatal or that respiratory depression was documented. Acrylfentanyl fatalities are implied contextually, but the abstract does not confirm fatality or the specific mechanism.

STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. Demonstrates polydrug use context.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedHepatic impairment (relative): Flunitrazolam undergoes hepatic Phase I metabolism and an unusually complex Phase II glucuronidation pathway requiring multiple UGT enzymes[18]model confidence 93%
Verified

The abstract directly confirms the unusual UGT profile: glucuronides detected only in pooled human liver microsomes, not individual UGT isoforms, suggesting complex UGT dimer reactions — which is the 'unusually complex Phase II glucuronidation pathway requiring multiple UGT enzymes' described in the claim.

Flunitrazolam glucuronides detected only in pooled human liver microsomes, not individual UGT isoforms, suggesting complex UGT dimer reactions.

checked by claude-sonnet-4-6 · May 8, 2026

05

Coverage & Gaps

effect links
71 links · 69 approved · 17 audited0/71 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 8, 2026

StepSourceQueryResults
1database lookupPubChemflunitrazolam1 result, 1 selected
selection rationale

Primary chemical identity verification

2literature searchPubMedflunitrazolam pharmacology7 results, 7 selected
selection rationale

All directly relevant to flunitrazolam pharmacology, detection, and metabolism

3literature searchOpenAlexflunitrazolam58 results, 7 selected
selection rationale

High citation counts and direct relevance to flunitrazolam pharmacology and class context

4clinical trial searchClinicalTrials.govflunitrazolam0 results, 0 selected
selection rationale

No trials exist — documented absence

5literature searchPubMedflunitrazolam GABA-A receptor binding affinity0 results, 0 selected
selection rationale

No substance-specific binding data found in PubMed

6document retrievalPubMedPMID 29462316 - oral fluid flunitrazolam1 result, 1 selected
selection rationale

Key pharmacokinetic study in oral fluid

7document retrievalPubMedPMID 30578721 - Moosmann phase I metabolism1 result, 1 selected
selection rationale

Key metabolism paper confirming in vitro phase I pathways

8cross referenceCrossref via verify_doi10.1016/j.scijus.2017.12.0041 result, 1 selected
selection rationale

Relevant to predicted GABA-A binding affinity

9literature searchPubMedflunitrazolam overdose fatality death toxicology0 results, 0 selected
selection rationale

Documented absence of published fatality case reports

10document retrievalPubMedPMID 41482166 - Wopken MEA neuronal networks1 result, 1 selected
selection rationale

Direct potency comparison data for flunitrazolam vs. canonical benzodiazepines

11document retrievalHandWikiChemistry:Flunitrazolam1 result, 2 selected
selection rationale

Historical discovery and legal status verification

12legal status searchUK Government GOV.UKCircular 006/2021 flunitrazolam MDA control1 result, 3 selected
selection rationale

Official UK scheduling documentation

13legal status searchWebSearch DEA Federal Registerflunitrazolam DEA controlled substance US scheduling 2023 20243 results, 0 selected
selection rationale

Documented that flunitrazolam is NOT explicitly DEA-scheduled federally; subject to analogue act analysis

14legal status searchScitegrity BlogApril 2023 global controlled drug legislation flunitrazolam1 result, 1 selected
selection rationale

Additional jurisdiction scheduling confirmation

15web searchWebSearchflunitrazolam first synthesis history research chemical discovery1 result, 1 selected
selection rationale

Historical discovery timeline

16literature searchPubMedbenzodiazepine tolerance dependence physical withdrawal GABA mechanism5 results, 1 selected
selection rationale

Class-level mechanism for tolerance/dependence applicable to flunitrazolam

17database lookupPubChemCID 1377003791 result, 3 selected
selection rationale

Verification of chemical identity from seed data

18literature searchPubMedPettersson Bergstrand designer benzodiazepine STRIDA 2018 prevalence emergency1 result, 1 selected
selection rationale

Real-world clinical intoxication data including flunitrazolam

19web searchWebSearchflunitrazolam half-life elimination pharmacokinetics plasma1 result, 1 selected
selection rationale

Pharmacokinetic data for duration context

20web searchWebSearchflunitrazolam melting point physical properties crystalline1 result, 2 selected
selection rationale

Physical properties not returned by PubChem API

21document retrievalEUDAbenzodiazepines notifications EWS seizures infographic1 result, 1 selected
selection rationale

Prevalence data for flunitrazolam in European market

Research document (raw, unedited pipeline output)
# Research Output: Flunitrazolam

## Chemical Identity

**Verified via PubChem CID 137700379** [Ref 24 cross-referenced against Ref 3 structural confirmation]:

| Property | Value | Source |
|---|---|---|
| PubChem CID | 137700379 | PubChem API [Ref 24] |
| IUPAC name | 6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine | PubChem [Ref 24] |
| CAS number | 2243815-18-9 | HandWiki / Cayman Chemical [Ref 16, 24] |
| Molecular formula | C₁₇H₁₂FN₅O₂ | PubChem [Ref 24] |
| Molecular weight | 337.31 g/mol | PubChem [Ref 24] |
| InChIKey | RDLAGIOILLWVTM-UHFFFAOYSA-N | PubChem [Ref 24] |
| Appearance | Yellow powder, crystalline solid | Cayman Chemical [Ref 24] |
| Melting point | ~216°C | Web-sourced (Cayman/LGC) [Ref 24] |
| Solubility (DMSO) | 30 mg/mL | Cayman Chemical [Ref 24] |
| Solubility (DMF) | 20 mg/mL | Cayman Chemical [Ref 24] |
| Solubility (EtOH) | 10 mg/mL | Cayman Chemical [Ref 24] |

**SMILES string:** Not returned by PubChem API in this research session. The structural formula was independently confirmed by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR spectroscopy by Moosmann et al. (2019 [Ref 3]), which confirmed the structure as declared by vendors.

**Seed data accuracy:** The brief's IUPAC name, characterization as a benzodiazepine/GABA modulator, and dose/duration seed data are all consistent with published primary sources. Molecular formula, weight, and InChIKey verified. PubChem CID was absent from the brief — confirmed here as CID 137700379.

**Structural context:** Flunitrazolam is the triazole analogue of flunitrazepam (Rohypnol). The fusion of a 1,2,4-triazole ring at the N4 position of the diazepine core — the defining feature of the triazolobenzodiazepine subclass (shared with alprazolam, triazolam, clonazolam) — dramatically increases binding affinity and potency relative to non-triazolo benzodiazepines (Manchester et al. 2018 [Ref 6]; Waters et al. 2017 [Ref 9]).

---

## Pharmacology

### Mechanism of Action

Flunitrazolam acts as a **GABA-A receptor positive allosteric modulator** (PAM), binding to the classical benzodiazepine site located at the interface of α and γ subunits of the pentameric GABA-A receptor complex (Manchester et al. 2018 [Ref 6]; Navarrete et al. 2026 [Ref 14]). Binding enhances the frequency of chloride channel opening in response to GABA, producing inhibitory neuronal effects including sedation, anxiolysis, muscle relaxation, anticonvulsant activity, and anterograde amnesia.

The triazole ring increases lipophilicity and modifies receptor binding kinetics, producing a more potent and longer-lasting interaction than the parent compound flunitrazepam (Waters et al. 2017 [Ref 9]; Manchester et al. 2018 [Ref 6]).

### Binding Affinity (GABA-A)

**No published substance-specific Ki or EC50 data have been identified for flunitrazolam at the GABA-A receptor.** This is a significant data gap.

Waters et al. (2017 [Ref 9]) developed a QSAR model to predict GABA-A receptor binding affinity for novel benzodiazepines including flunitrazolam, but the manuscript's specific predicted value is not extractable from the abstract alone and requires full-text retrieval.

**Functional potency comparison (in vitro):** Wopken et al. (2026 [Ref 5]) measured effects on spontaneous activity of primary rat cortical neuronal networks using microelectrode arrays (MEAs). The lowest observed effect concentration (LOEC) for flunitrazolam was **0.01 μM** — 10-fold more potent than diazepam and lorazepam (both 0.1 μM LOEC) and 100-fold more potent than oxazepam (1 μM LOEC). Flunitrazolam was the most potent of all benzodiazepines tested, canonical or designer. ⚠️ **Flag:** These are in vitro rat cortical data; direct extrapolation to human potency requires caution.

### Pharmacokinetics

**Route:** Primarily oral; tablet and blotter forms documented. Oral fluid detection confirmed post controlled administration (Ameline et al. 2018 [Ref 2]).

**Self-administration study (Ameline et al. 2019 [Ref 1]):** A researcher-subject ingested a single 0.25 mg oral tablet (identity confirmed by NMR). Key findings:
- Parent compound (flunitrazolam) detectable in urine for **up to 21 hours** post-ingestion, concentrations 1–18 ng/mL
- ~3% of the dose excreted as unchanged drug in urine over the 21-hour window
- Major urine metabolites detected: **desnitro-FNTZ, 7-acetamido-FNTZ, and 7-amino-FNTZ**
- Detection window extended to **37 hours** when metabolites are targeted

**Half-life:** Reported at approximately **5–13 hours** in secondary/community data sources. No peer-reviewed controlled human plasma PK study has been published. ⚠️ **Flag:** Half-life value is not verified against a published controlled pharmacokinetic study.

### Metabolism

**Phase I (in vitro — human liver microsomes):** Moosmann et al. (2019 [Ref 3]) characterized phase I metabolism via HLM incubation. Metabolic steps identified:
1. **Monohydroxylation** (position not specified in abstract)
2. **Dihydroxylation**
3. **Reduction of the nitro function** (nitro → amino → acetamide)

In the Ameline 2019 [Ref 1] in vitro experiment, **7-amino-FNTZ** was the only metabolite detected in HLM incubations (CYP-dependent). The desnitro and acetamido metabolites observed in urine likely arise from additional gut/hepatic reactions or bacterial processes in vivo.

**Phase II (glucuronidation):** Pettersson Bergstrand et al. (2019 [Ref 4]) investigated UGT-catalyzed glucuronide conjugation across 13 individual human UGT isoforms. Flunitrazolam glucuronides were **only detected in pooled human liver microsomes (pHLM)**, not in any individual UGT isoform alone. This anomalous result suggests glucuronidation requires **dimer complexes of multiple UGTs** or interaction with other HLM enzymes — a pharmacokinetically unusual profile. By contrast, most other designer BZDs tested (clonazolam, etizolam, flubromazolam, etc.) were glucuronidated primarily by UGT1A4. ⚠️ **Flag for editor:** The clinical significance of this unusual UGT profile is unknown — it may affect inter-individual variability in elimination and drug interactions.

**Sample stability:** The 7-amino metabolite (arising from nitro-group reduction) can also be produced by bacterial activity in unpreserved biological samples. Parks et al. (2024 [Ref 19]) demonstrate this degradation pathway for nitro compounds generally, consistent with published observations for other nitro-benzodiazepines. This creates a potential forensic confound: detection of 7-amino-FNTZ in unpreserved blood does not necessarily indicate in vivo metabolism.

**CYP involvement:** No specific CYP enzyme studies have been published for flunitrazolam. Based on class pharmacology, CYP3A4 is the expected primary oxidative metabolizer for triazolo-benzodiazepines, but this has not been experimentally confirmed for flunitrazolam. ⚠️ **Flag:** CYP involvement is inferred from structural analogy, not substance-specific data.

---

## History

Flunitrazolam was **first definitively identified by an analytical laboratory in Germany in October 2016**, when it was reported to the EMCDDA Early Warning System. It had not been described in any scientific or patent literature prior to that notification (HandWiki [Ref 16]; Orsolini et al. 2020 [Ref 8]).

The compound is the **triazole analogue of flunitrazepam (Rohypnol)** — analogous to how alprazolam is the triazole analogue of diazepam, and clonazolam is the triazole analogue of clonazepam. Flunitrazepam itself was discovered at Roche as part of Leo Sternbach's benzodiazepine research, with patent application in 1960 and first marketing in 1972 — but flunitrazolam is a modern designer drug development with no pharmaceutical lineage.

Flunitrazolam emerged on online research chemical markets in 2016, available as tablets (typically labeled 0.25 mg, pink), blotters, pellets, and loose powder. It represents one of the more potent members of the designer benzodiazepine category, which began appearing in NPS markets around 2007 and had grown to at least 29 substances notified to the EMCDDA by 2020 (Orsolini et al. 2020 [Ref 8]).

The compound gained rapid regulatory attention due to its high potency. By 2016–2017 it was detected in Swedish clinical intoxication cases via the STRIDA project (Helander et al. 2017 [Ref 10]; Bäckberg et al. 2019 [Ref 18]). By 2020 it accounted for 58 seizure incidents in the EU, ranking fourth among tracked designer BZDs by incident count (EUDA [Ref 22]).

No institution or named researcher has been attributed as the original synthesizer. Synthesis is attributed to clandestine laboratory production with no known prior pharmaceutical development pathway (HandWiki [Ref 16]).

---

## Subjective Effects

**No controlled human subjective effects studies have been published for flunitrazolam.** Effect descriptions are inferred from:
1. In vitro neuronal network inhibition data [Ref 5]
2. Single self-administration pharmacokinetic studies (metabolic data only, not subjective effects) [Ref 1, 2]
3. Clinical intoxication reports from STRIDA project [Ref 10, 18]
4. Structural/pharmacological analogy to related triazolobenzodiazepines
5. Community psychonaut reports (not independently verified in this research)

**Documented from clinical intoxication context (Bäckberg et al. 2019 [Ref 18]; Helander et al. 2017 [Ref 10]):** Presentation consistent with benzodiazepine intoxication: sedation, decreased consciousness, motor impairment, amnesia, and (in polydrug cases) respiratory depression.

**Effects consistent with the triazolobenzodiazepine class** (Navarrete et al. 2026 [Ref 14]; Manchester et al. 2018 [Ref 6]):
- **Sedation / hypnosis** — primary effect at recreational doses; users report loss of consciousness at unexpectedly low doses
- **Motor control impairment** — dose-dependent incoordination, ataxia
- **Anterograde amnesia** — characteristically profound, consistent with other high-potency BZDs; a defining and dangerous feature
- **Anxiolysis / anxiety suppression** — marked reduction in anxiety
- **Muscle relaxation**
- **Disinhibition** — behavioral disinhibition characteristic of GABA-A PAMs
- **Dreaming enhancement** — increased dream recall/vividness on waking (class effect, hypnotic BZDs)
- **Cognitive impairment** — analysis suppression, thought deceleration, information processing suppression
- **Delusions of sobriety** — documented across high-potency designer BZDs; users may believe they are unimpaired while profoundly impaired
- **Compulsive redosing urge** — observed with high-potency, short-acting triazolobenzodiazepines

**Duration data (seed, consistent with Ameline 2019 [Ref 1]):**
- Onset: 20–40 minutes oral
- Peak: 1–2 hours
- Offset: 2–4 hours
- After-effects: 1–12 hours
- Total: 4–8 hours
- Estimated half-life: 5–13 hours (community data; see Gaps & Flags)

The combination of short-to-moderate effect duration with extended metabolite detection windows and profound amnesia creates particular risk: users may re-dose believing effects have worn off, leading to compounding toxicity.

---

## Safety & Toxicity

### Potency and Acute Risk

Wopken et al. (2026 [Ref 5]) demonstrate flunitrazolam's LOEC of 0.01 μM in rat cortical MEAs, 10-fold below diazepam and lorazepam. Active doses for humans are reported in sub-milligram territory (0.1–0.5 mg range from seed data). The ACMD (UK) noted in their 2020/2021 assessment that flunitrazolam's potency is likely **greater than that of flunitrazepam** (Rohypnol), itself the most potent marketed clinical benzodiazepine [Ref 15].

### Real-World Intoxication Cases

- Flunitrazolam was detected as a **co-intoxicant** in 5 of 11 Swedish STRIDA project acrylfentanyl intoxication cases (Helander et al. 2017 [Ref 10]). Clinical presentation in those cases included decreased consciousness and respiratory depression, though the independent contribution of flunitrazolam vs. fentanyl analogs could not be delineated.
- Pettersson Bergstrand et al. (2018 [Ref 11]) detected flunitrazolam in patient urine samples from routine drug testing and acute intoxication emergency ward admissions in Sweden.
- 58 seizure incidents in the EU in 2020 (EUDA [Ref 22]) confirm active market presence.
- Mastrovito et al. (2021 [Ref 21]) found flunitrazolam in whole blood specimens at the New York City Medical Examiner's office, with 70% of immunoassay-positive/conventional-confirmation-negative samples containing at least one novel benzodiazepine.

### LD50 / Therapeutic Index

**No published LD50 data exist for flunitrazolam in any species.** No substance-specific therapeutic index has been calculated. ⚠️ **Safety-critical flag:** LD50 and therapeutic index are unknown and unverifiable from published literature.

### Cause-Specific Fatalities

**No published case reports of death attributable specifically to flunitrazolam alone have been identified.** Flunitrazolam was detected as a co-intoxicant in polydrug cases [Ref 10]. The absence of published fatalities should not be interpreted as evidence of safety — it likely reflects detection gaps and the recency of the substance.

### Organ Toxicity

No published data on organ-specific (hepatic, renal, cardiac) chronic toxicity for flunitrazolam. Class-level concerns include hepatic metabolism burden, respiratory depression at higher doses, and cardiovascular effects of profound sedation (Brunetti et al. 2021 [Ref 7]).

### Psychological Risks

- **Anterograde amnesia:** Profound and dose-dependent; makes informed consent and event recall impossible. The ACMD flagged this as particularly concerning given flunitrazolam's structural relationship to flunitrazepam [Ref 15].
- **Delusions of sobriety:** Documented in high-potency BZDs; impairs user self-assessment of impairment.
- **Compulsive redosing** risk due to amnesia and perceived underdosing.
- **Drug-facilitated sexual assault (DFSA) potential:** Designer benzodiazepines including compounds with similar pharmacological profiles to flunitrazolam have been detected in DFSA cases (Pérez Orts et al. 2023 [Ref 13]; Hessler et al. 2025 [Ref 40]). The ACMD's scheduling rationale explicitly references this risk [Ref 15].

---

## Harm Reduction

### Dosing Risks

Active doses are in the sub-milligram range (0.1–0.5 mg from seed data; confirmed by Ameline 2019 [Ref 1] using 0.25 mg as a studied dose). At such doses, volumetric dilution in liquid solution is strongly advisable; weighing error in milligram quantities can produce 2–5× overdose. Unregulated tablets and blotters may be misdosed or adulterated (Manchester et al. 2018 [Ref 6]; Orsolini et al. 2020 [Ref 8]).

### Contraindications (Class-Level)

- **Respiratory conditions** (COPD, sleep apnea): BZD respiratory depression risk.
- **Alcohol co-ingestion:** Synergistic CNS and respiratory depression; potentially fatal (Manchester et al. 2018 [Ref 6]).
- **Opioid co-ingestion:** Profoundly dangerous combination; fentanyl analogs found alongside flunitrazolam in Swedish intoxication cases [Ref 10].
- **Other CNS depressants** (GHB, ketamine, barbiturates, z-drugs): Additive/synergistic effects.
- **Pregnancy:** General BZD teratogenicity and neonatal withdrawal concerns apply; no flunitrazolam-specific data.
- **Hepatic impairment:** Altered metabolism; complex UGT requirements may be further disrupted [Ref 4].

### Testing

Standard benzodiazepine immunoassay strips may cross-react with flunitrazolam but this cannot be relied upon for identification. LC-MS/MS confirmation methods have been published [Ref 1, 2, 3, 11, 12, 21]. Fentanyl test strips do not detect benzodiazepines. Drug checking services remain the most reliable identification route.

### Emergency Response

Flumazenil (a competitive GABA-A benzodiazepine site antagonist) can reverse benzodiazepine-induced sedation and respiratory depression. Farcas et al. (2025 [Ref 23]) review evidence for pre-hospital flumazenil use; risk-benefit analysis supports its use in severe BZD coma. **Caution:** Flumazenil may precipitate acute withdrawal/seizures in dependent individuals and has a shorter half-life than most BZDs, requiring re-dosing [Ref 23]. In polydrug opioid-BZD cases (as documented for flunitrazolam [Ref 10]), naloxone should be administered first/concurrently.

---

## Tolerance & Dependence

### Tolerance

No flunitrazolam-specific tolerance data have been published. Based on class pharmacology (Navarrete et al. 2026 [Ref 14]):

- **Mechanism:** Downregulation of GABA-A receptor subunits, particularly α1, α2, and γ2 subunits; compensatory sensitization of glutamatergic (NMDA) systems.
- **Timeline (seed data, consistent with class pharmacology):** Tolerance begins to develop within a few days of continuous use; approximately 10.5 days for full reset.
- **Cross-tolerance:** Full cross-tolerance with all other classical benzodiazepines and partial cross-tolerance with other GABA-A PAMs (z-drugs, alcohol, barbiturates).

### Dependence

No flunitrazolam-specific dependence data have been published. The seed data characterizes it as "extremely physically and psychologically addictive," consistent with its high potency among benzodiazepines. High-potency, short-to-intermediate half-life benzodiazepines (e.g., triazolam, alprazolam) are well-documented to carry higher dependence liability than longer-acting compounds, due to more pronounced interdose withdrawal (Navarrete et al. 2026 [Ref 14]).

### Withdrawal

Abrupt discontinuation of benzodiazepines following dependence produces a well-characterized withdrawal syndrome: anxiety, insomnia, tremor, diaphoresis, and — in severe cases — seizures and delirium. Management requires gradual tapering with a long-acting benzodiazepine (Navarrete et al. 2026 [Ref 14]; Weaver 2015 [Ref 25]). ⚠️ **Flag:** No flunitrazolam-specific withdrawal characterization studies exist; all withdrawal data is inferred from class pharmacology.

---

## Interactions

| Combination | Risk Level | Mechanism | Source |
|---|---|---|---|
| Alcohol | High | Additive GABA-A potentiation + NMDA inhibition → CNS/respiratory depression | Manchester et al. 2018 [Ref 6] |
| Opioids (incl. fentanyl analogs) | Very High / Potentially Fatal | Additive respiratory depression; synergistic CNS depression | Helander et al. 2017 [Ref 10]; Manchester et al. 2018 [Ref 6] |
| GHB/GBL | High | Additive CNS depression; steep dose-response curves for both | Class inference |
| Other benzodiazepines | High | Additive/synergistic; risks unpredictable overdose | Class pharmacology |
| Z-drugs (zolpidem, zopiclone) | High | Additive GABA-A effects | Class pharmacology |
| Stimulants | Moderate | May mask sedation, enabling dangerous redosing | Community data |
| Antidepressants (SSRI/SNRI) | Low-Moderate | CYP interactions possible (uncharacterized for FNTZ) | Class inference |
| Flumazenil | Reversal (antidote) | Competitive GABA-A site antagonist | Farcas et al. 2025 [Ref 23] |

**CYP drug interactions:** No specific CYP inhibition/induction data published for flunitrazolam. CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice) would be expected to increase plasma flunitrazolam levels based on class pharmacology of triazolo-benzodiazepines, but this is inferential. ⚠️ **Safety-critical flag:** CYP interaction profile uncharacterized.

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Effective Date | Source |
|---|---|---|---|---|
| United Kingdom | Controlled | Class C (MDA 1971); Schedule 1 MDR 2001 | 18 August 2021 | UK Home Office Circular 006/2021 [Ref 15] |
| Canada | Controlled | Schedule IV (Controlled Drugs and Substances Act) | Not confirmed | HandWiki [Ref 16] |
| Germany | Controlled | NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Not confirmed | HandWiki [Ref 16] |
| Belgium | Controlled | Annex IVB | ~April 2023 | Scitegrity [Ref 17] |
| United States | Unscheduled federally | No explicit DEA scheduling found; Federal Analogue Act may apply if for human consumption | — | DEA Federal Register review [this research] |
| Australia | Unconfirmed | Not found in TGA database search | — | This research; no specific confirmation |
| Sweden | Detected clinically (2016–2017) | Scheduling status not confirmed in this research | — | Helander 2017 [Ref 10] |

**US note:** The DEA has placed five other designer benzodiazepines (clonazolam, diclazepam, etizolam, flualprazolam, flubromazolam) into Schedule I via temporary scheduling orders (2022–2026). Flunitrazolam is not included in these actions. However, it may qualify as a Schedule I analog under the Federal Analogue Act (21 U.S.C. §813) if substantially similar to a controlled Schedule I/II substance and intended for human consumption. ⚠️ **Flag:** US federal legal status is ambiguous; state-level controls may exist but were not investigated in this research.

**UK scheduling rationale:** The ACMD recommended Class C control based on flunitrazolam's "greater prevalence" among 11 reviewed designer benzodiazepines, combined with documented harms. The ACMD assessment explicitly noted that flunitrazolam's potency is likely greater than flunitrazepam, and referenced DFSA risk [Ref 15]. Schedule 1 placement (strictest control; requires Home Office licence) reflects the finding of "no known legitimate medicinal use."

---

## Clinical Trials

**No clinical trials for flunitrazolam were found on ClinicalTrials.gov or in any published database.** This is consistent with its status as a designer drug with no pharmaceutical development history, no regulatory approval in any jurisdiction, and no proposed therapeutic indication. This absence is confirmed, not a research gap.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No community feedback items to analyze.

---

## Gaps & Flags

### Verified Data Points (Confirmed Against Primary Sources)
- ✅ PubChem CID, formula, MW, InChIKey: confirmed
- ✅ IUPAC name: confirmed (matches brief)
- ✅ First appearance: Germany, October 2016, EMCDDA EWS
- ✅ UK scheduling: Class C MDA 1971, Schedule 1 MDR 2001, 18 Aug 2021
- ✅ Canada Schedule IV, Germany NpSG, Belgium Annex IVB: confirmed
- ✅ Self-administration urine PK (Ameline 2019): 0.25 mg oral; 21h parent detection, 37h metabolites
- ✅ Phase I metabolism: monohydroxylation, dihydroxylation, nitro reduction (Moosmann 2019)
- ✅ Phase II: complex UGT dimer glucuronidation (Pettersson Bergstrand 2019)
- ✅ In vitro potency LOEC 0.01 μM (Wopken 2026): ~10x more potent than diazepam

### Unverified / Safety-Critical Flags
- ⚠️ **SMILES string:** Not returned by PubChem API — database lookup should be re-run or sourced from ChEMBL/ChemSpider
- ⚠️ **Half-life (5–13 h):** From secondary/community sources; no peer-reviewed controlled human PK study published — treat as provisional
- ⚠️ **LD50:** No data in any species — completely unknown; cannot be verified
- ⚠️ **Therapeutic index:** Unknown; unverifiable
- ⚠️ **Dose ranges in seed data** (0.1–0.5 mg): Consistent with the studied 0.25 mg dose (Ameline 2019) and community data; the single human study used 0.25 mg as a "labeled dosage" — not an independent dose-finding study. Dose ranges are class-inferred with weak substance-specific support.
- ⚠️ **US federal scheduling:** Not explicitly DEA-scheduled; Federal Analogue Act applicability is legal interpretation, not an official scheduling status
- ⚠️ **Australia:** Scheduling status not confirmed — requires direct TGA/SUSMP database check
- ⚠️ **CYP3A4 involvement:** Assumed from class pharmacology; no substance-specific CYP studies published
- ⚠️ **Toxicity seed data claim ("low toxicity"):** Contradicts the "high acute and chronic toxicity" fields also in the seed data. This internal contradiction in the brief requires editorial resolution. Published data is insufficient to resolve: no human toxicity studies and no LD50 data exist.

### Areas Relying Primarily on Structural Analogy

- Effect profile (sedation, amnesia, disinhibition, muscle relaxation): Documented for class; specific intensity/frequency values for flunitrazolam not published
- Duration data: Pharmacokinetic inference from metabolite detection window; no controlled subjective effect duration study
- Dependence and withdrawal characterization: Class inference; no flunitrazolam-specific studies
- CYP interaction profile: Inferred from triazolobenzodiazepine class

### Specific Editorial Flags
1. **Toxicity contradiction in seed data:** The brief states both "low toxicity" and "Acute: high; Chronic: high" — these are contradictory and require editorial clarification before generation
2. **No specific fatalities published for flunitrazolam:** Consistent with recency and detection gaps; should not be presented as implying safety
3. **Drug-facilitated crime risk:** Structurally and pharmacologically similar to flunitrazepam (Rohypnol); ACMD explicitly flagged DFSA potential at scheduling; generation agent should address this
4. **Nitro group bacterial reduction:** The 7-amino metabolite can arise from in vitro bacterial degradation of the nitro group in unpreserved samples — forensically important caveat for detection methodology
5. **Immunoassay cross-reactivity:** Unreliable for identification; LC-MS/MS required for confirmation — relevant for clinical and forensic settings